Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-Stroke Patients.

Trial Profile

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-Stroke Patients.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Aphasia; Stroke
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 31 Mar 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2016 as per ClinicalTrials.gov record.
    • 05 Sep 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top